July 2024 Insights Into Three SEHK Stocks Estimated Below Intrinsic Value

In a week marked by modest gains in the Hang Seng Index and ongoing concerns about China's economic slowdown, investors are closely monitoring opportunities within Hong Kong's stock market. Amidst these conditions, identifying stocks that appear undervalued relative to their intrinsic value could be particularly compelling for those looking to invest wisely in a fluctuating market environment.

Top 10 Undervalued Stocks Based On Cash Flows In Hong Kong

Name	Current Price	Fair Value (Est)	Discount (Est)
China Resources Mixc Lifestyle Services (SEHK:1209)	HK$24.55	HK$48.82	49.7%
United Energy Group (SEHK:467)	HK$0.30	HK$0.57	47.7%
China Cinda Asset Management (SEHK:1359)	HK$0.68	HK$1.29	47.3%
West China Cement (SEHK:2233)	HK$1.12	HK$2.16	48.2%
Shanghai INT Medical Instruments (SEHK:1501)	HK$25.25	HK$48.27	47.7%
Zijin Mining Group (SEHK:2899)	HK$17.66	HK$32.13	45%
Super Hi International Holding (SEHK:9658)	HK$14.40	HK$26.17	45%
Melco International Development (SEHK:200)	HK$5.23	HK$10.40	49.7%
Vobile Group (SEHK:3738)	HK$1.17	HK$2.30	49.2%
Q Technology (Group) (SEHK:1478)	HK$3.91	HK$7.37	46.9%

Click here to see the full list of 44 stocks from our Undervalued SEHK Stocks Based On Cash Flows screener.

Underneath we present a selection of stocks filtered out by our screen

China Cinda Asset Management (SEHK:1359)

Overview: China Cinda Asset Management Co., Ltd. operates in the acquisition, management, investment, and disposal of distressed assets from financial and non-financial institutions across the People’s Republic of China and Hong Kong, with a market capitalization of approximately HK$25.95 billion.

Operations: The company generates revenue primarily through its financial services and distressed asset management segments, with CN¥12.71 billion from financial services and CN¥11.04 billion from distressed asset management, including financial investment and asset management activities.

Estimated Discount To Fair Value: 47.3%

China Cinda Asset Management, trading at HK$0.68, is valued below our fair value estimate of HK$1.29, indicating substantial undervaluation based on cash flows. Despite a recent dividend decrease to RMB 0.4576 per 10 shares and unstable dividend history, the firm's forecasted revenue growth at 31.3% per year significantly outpaces the Hong Kong market's 7.7%. However, its debt is poorly covered by operating cash flow, and earnings quality is affected by large one-off items.

• Our comprehensive growth report raises the possibility that China Cinda Asset Management is poised for substantial financial growth.
• Click to explore a detailed breakdown of our findings in China Cinda Asset Management's balance sheet health report.

West China Cement (SEHK:2233)

Overview: West China Cement Limited operates as an investment holding company that manufactures and sells cement and cement products in the People's Republic of China, with a market capitalization of approximately HK$6.11 billion.

Operations: The company generates CN¥6.31 billion from operations in the People's Republic of China and CN¥2.77 billion from overseas markets.

Estimated Discount To Fair Value: 48.2%

West China Cement, priced at HK$1.12, is significantly undervalued with a fair value estimate of HK$2.16. It's set to outperform the Hong Kong market with expected annual revenue and earnings growth of 20.2% and 46.9%, respectively. Despite this potential, concerns include a high debt level and recent insider selling, alongside profit margins dropping to 4.7% from last year's 14.3%. Additionally, recent corporate governance changes and a reduced dividend highlight operational adjustments.

• In light of our recent growth report, it seems possible that West China Cement's financial performance will exceed current levels.
• Unlock comprehensive insights into our analysis of West China Cement stock in this financial health report.

Yunkang Group (SEHK:2325)

Overview: Yunkang Group Limited, a medical operation service provider based in the People's Republic of China, has a market capitalization of approximately HK$5.99 billion.

Operations: The company generates its revenue primarily through the provision of diagnostic testing services to hospitals and non-medical clients, totaling CN¥0.89 billion.

Estimated Discount To Fair Value: 14.3%

Yunkang Group Limited, trading at HK$9.96 against a fair value of HK$11.63, appears undervalued based on cash flows. Analysts predict a 40.5% potential price increase, with revenue growth expected at 10.9% annually, outpacing the Hong Kong market's 7.7%. Although its Return on Equity is projected low at 2.4%, the company is forecast to turn profitable within three years, showing promising profit growth significantly above the market average.

• Insights from our recent growth report point to a promising forecast for Yunkang Group's business outlook.
• Dive into the specifics of Yunkang Group here with our thorough financial health report.

Make It Happen

• Access the full spectrum of 44 Undervalued SEHK Stocks Based On Cash Flows by clicking on this link.
• Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.
• Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.

Interested In Other Possibilities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com